Home » Stocks » MYOS

MYOS RENS Technology Inc. (MYOS)

Nov 18, 2020 - Stock symbol was changed to MDVL
Stock Price: $1.01 USD 0.00 (0.00%)
Updated Nov 17, 2021 4:00 PM EST
Market Cap 12.31M
Revenue (ttm) 1.48M
Net Income (ttm) -3.64M
Shares Out 11.85M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Nov 17, 2021
Last Price $1.01
Previous Close $1.01
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.05
Day's Range 1.01 - 1.09
Day's Volume 218,840
52-Week Range 0.74 - 3.85

News

Hide News
Business Wire - 3 months ago

MISSISSAUGA, Ontario & CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--MedAvail, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds pharmacy services directly into clinics ...

PRNewsWire - 3 months ago

CEDAR KNOLLS, N.J., Nov. 12, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS) As previously announced, on June 30, 2020, MYOS RENS Technology, Inc., a Ne...

PRNewsWire - 3 months ago

CEDAR KNOLLS, N.J., Nov. 6, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary ...

PRNewsWire - 7 months ago

NEW YORK, July 7, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MYOS RENS Technology Inc. ("MY...

PRNewsWire - 7 months ago

CEDAR KNOLLS, N.J., July 7, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a...

PRNewsWire - 8 months ago

NEW YORK, July 2, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between MYOS RENS Technology Inc. (NASDAQ: MYOS) and MedAvail, I...

Newsfile Corp - 8 months ago

New York, New York--(Newsfile Corp. - July 2, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased MYOS RENS Technology Inc. (NASD...

Benzinga - 8 months ago

Shares of nutrition company MYOS Corporation (NASDAQ: MYOS) were more than doubling Wednesday.

PRNewsWire - 8 months ago

CEDAR KNOLLS, N.J. and MISSISSAUGA, Ontario, June 30, 2020 /PRNewswire/ -- MYOS RENS Technology, Inc. ("MYOS") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a pr...

PRNewsWire - 9 months ago

CEDAR KNOLLS, N.J., May 14, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition th...

Seeking Alpha - 9 months ago

MYOS RENS Technology's (MYOS) CEO Joseph Mannello on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 11 months ago

MYOS RENS Technology Inc (MYOS) CEO Joseph Mannello on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

MYOS RENS Technology Inc (MYOS) CEO Joseph Mannello on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

MYOS RENS Technology Inc. (MYOS) CEO Joseph Mannello on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

MYOS RENS Technology Inc. (MYOS) CEO Joseph Mannello on Q4 2018 Results - Earnings Call Transcript

About MYOS

MYOS RENS Technology focuses on the discovery, development, and commercialization of nutritional ingredients, functional foods, and other technologies that enhance muscle health and performance. The company primarily focuses on developing Fortetropin for the therapeutic markets, including the treatment of sarcopenia, cachexia, anorexia, obesity, and muscular disorders. Its products include Qurr line of products to support muscle well-being and fitness; Yolked line of products for collegiate and professional athletes; and Myos Canine Muscle Form... [Read more...]

Industry
Drug Manufacturers—Specialty & Generic
Founded
2007
CEO
Joseph Manello
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
MYOS
Full Company Profile

Financial Performance

In 2019, MYOS's revenue was $1.03 million, an increase of 186.67% compared to the previous year's $360,000. Losses were -$4.26 million, 32.1% more than in 2018.

Financial Statements